Sabatolimab is under clinical development by Novartis and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Sabatolimab’s likelihood of approval (LoA) and phase transition for Myelofibrosis took place on 16 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 16 Nov 2022 increased Sabatolimab’s LoA and PTSR for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and increased LoA and PTSR for Post-Polycythemia Vera Myelofibrosis (PPV-MF).
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sabatolimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Sabatolimab overview
Sabatolimab is under development for the treatment of solid tumors including glioblastoma multiforme, gliosarcoma and relapsed or refractory and de novo acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, primary myelofibrosis including post-essential thrombocythemia (ET) (PET-MF) and post-polycythemia vera (PV) myelofibrosis (PPV-MF). It is administered intravenously. The monoclonal antibody acts by targeting T cell immunoglobulin mucin-3 (TIM-3). It is a new molecular entity (NME).
It was also under development for the treatment of melanoma, non-small cell lung cancer, small cell lung cancer, renal cell carcinoma.
Novartis overview
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Quick View Sabatolimab LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|